UCB

News

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.

News

UCB gets an EU recommendation for the first therapy for thymidine kinase 2 deficiency (TK2d), plus other CHMP decisions.

News

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

People living with thymidine kinase 2 deficiency (TK2d), a vanishingly rare and often fatal genetic disorder, finally have an approved therapy.

News

UCB's experimental medicine for TK2d, currently under regulatory review, offers hope to patients with the devastating rare disease.

News

Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.